Video

Dr. Hoos on a Possible Successor Drug to Ipilimumab

Author(s):

Axel Hoos, MD, PhD

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the multiple immunotherapy agents in development, including the most advanced anti-PD-1 agent MDX-1106 which has a similar mechanism of action to ipilimumab (Yervoy).

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Related Content
Non–Small Cell Lung cancer | Image Credit: © Axel Kock – stock.adobe.com
December 21st 2024

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ovarian Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 9th 2024

Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Monica H. Vetter, MD
December 5th 2024

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer

ReisMedia - stock.adobe.com
December 4th 2024

NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma